基于1,5-二胺的2-替代HDAC抑制剂对人类固体和急性髓性白血病细胞系施加抗癌作用
Simona De Vita1, Sara Meninno2, Lucia Capasso3
1Department of Pharmacy, University of Salerno, Via Giovanni Paolo II, 132, 84084 Fisciano, Italy.
Bioorganic & medicinal chemistry
|August 23, 2023
概括
我们开发了使用1,5-西胺支架的新型基因素脱乙酶抑制剂 (HDACi). 这些化合物显示出强大的纳米分子HDAC抑制,并对癌细胞表现出细胞毒性作用,突出显示了它们作为流行药的潜力.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 基因组脱乙酶 (HDACs) 是细胞通路的关键调节者,是重要的药物标.
- 开发新的HDAC抑制剂对于新的表观遗传疗法至关重要.
研究的目的:
- 设计,合成和评估一系列新型的2-替代1,5-西胺衍生物作为强大的基因素脱乙酶抑制剂.
- 探索这些化合物与HDAC异型之间的结构-活性关系.
主要方法:
- 构建一个虚拟的组合图书馆和对HDAC异形进行分子对接.
- 优化合成路径的racemic和富含enantio的西胺衍生物.
- 在体外评估HDAC抑制活性,细胞毒性,细胞循环停止,以及对基因素乙化标记物的西斑分析.
主要成果:
- 识别具有纳米分子范围的IC50值的强效HDAC抑制剂,特别是含有硫部分的那些.
- 对U937和HCT116癌细胞系显著细胞毒性作用的证明.
- 观察G2/M阶段停止和基因素乙化关键标记物的调制 (H3K9/14,乙-素,p21).
结论:
- 合成的2-替代的1,5-西胺衍生物显示出有前途的HDAC抑制活性和抗癌性质.
- 这些化合物,在减少和氧化两种形式,代表了开发新型表观遗传药物的宝贵类.
- 这些发现强调了针对HDACs的治疗潜力,使用新的西胺基化合物.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
332
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
332
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K


